Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022
SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a…
SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a…
The recommended phase 2 dose was determined at 480 mg AFM24 has demonstrated a well-managed…
– Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and…
– Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – –…
– First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as…
Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and…
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented…
– Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse…
TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against…
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
ZURICH, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — Araris Biotech AG, a company pioneering a…
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with…
MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition…
Data demonstrates the potential for de novo engineering of novel synthetic cytotoxic effector cells that show significant…
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide…
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company…
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their…
GENEVA, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — iOnctura SA, a clinical-stage oncology company targeting…
– Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer…
First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate…